Abbvie Endocrine Inc patents expiration
1. Lupron Depot patents expiration
LUPRON DEPOT's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8815801 | ABBVIE ENDOCRINE INC | Controlled release composition and method of producing the same |
Jun, 2022
(1 year, 2 months ago) | |
| US8921326 | ABBVIE ENDOCRINE INC | Sustained-release composition and method for producing the same |
Feb, 2031
(7 years from now) | |
Drugs and Companies using LEUPROLIDE ACETATE ingredient
Market Authorisation Date: 22 December, 1995
Treatment: Palliative treatment of prostate cancer
Dosage: INJECTABLE;INJECTION
More Information on Dosage
LUPRON DEPOT family patents
2. Lupron Depot-ped Kit patents expiration
LUPRON DEPOT-PED KIT's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9617303 | ABBVIE ENDOCRINE INC | Sustained-release composition and method for producing the same |
Mar, 2028
(4 years from now) | |
| US8921326 | ABBVIE ENDOCRINE INC | Sustained-release composition and method for producing the same |
Feb, 2031
(7 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Strength (NS) | Apr 14, 2026 |
Drugs and Companies using LEUPROLIDE ACETATE ingredient
Market Authorisation Date: 16 April, 1993
Treatment: Treatment of pediatric patients with central precocious puberty
Dosage: POWDER;INTRAMUSCULAR
More Information on Dosage
LUPRON DEPOT-PED KIT family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic